Cambridge Cognition and ActiGraph join forces to advance the use of digital health technologies in central nervous system (CNS) trials, offering comprehensive assessments and objective data collection for improved clinical insights.
Accelerating CNS Trials with Digital Measurements: Cambridge Cognition Partners with ActiGraph
( Credit to: Digitalhealth )
Cambridge Cognition PLC, a neuroscience technology company, has announced a strategic partnership with ActiGraph to accelerate the adoption of digital measurements in central nervous system (CNS) trials. By joining ActiGraph's Accelerant partnership program, Cambridge Cognition aims to simplify access to raw data streams for contract research organizations and technology vendors, thus advancing the use of digital health technologies in clinical development.
The partnership between Cambridge Cognition and ActiGraph will provide a comprehensive range of assessments to gain a holistic view of both mental and physical capabilities. By leveraging their expertise in digital data collection, the two companies aim to enhance assessment capabilities in CNS trials, particularly in areas with significant unmet needs such as schizophrenia and dementia.
ActiGraph's Chief Scientific Officer, Christine Guo, emphasized the importance of digital health technologies in collecting objective data during a patient's everyday life. In CNS disorders, where conventional assessments are susceptible to subjective biases, digital measurements offer a more reliable and unbiased approach. Guo expressed excitement about the partnership with Cambridge Cognition, as it will provide advanced clinical insights to study teams conducting CNS trials.
Cambridge Cognition specializes in touch-screen and voice-based digital assessments of cognition and other brain health indicators. Their suite of e-clinical technology solutions can be used both in-clinic and at home, offering flexibility for pharmaceutical companies and research institutions to capture crucial clinical measures accurately.
Francesca Cormack, Chief Scientist at Cambridge Cognition, highlighted the challenges posed by the heterogeneous symptoms of CNS disorders, which often impact daily life and are inadequately addressed by existing treatments. The partnership with ActiGraph represents a promising combination of objective digital measures of actigraphy, speech, and cognition. This collaboration aims to expedite the development of treatments for patients and improve the efficiency of clinical trials.
Both Cambridge Cognition and ActiGraph are renowned for their contributions to research projects, providing technological solutions for academic researchers. By combining actigraphy data with brain health assessments, the partnership may pave the way for more accurate multi-modal digital biomarkers in the future.
In summary, Cambridge Cognition's strategic partnership with ActiGraph seeks to accelerate the adoption of digital measurements in CNS trials. By leveraging their expertise in digital data collection, the two companies aim to enhance assessment capabilities in areas with significant unmet needs. This collaboration holds the potential to improve the development of treatments for CNS disorders and streamline clinical trials.